Overview of Radiopharmaceuticals for Diagnosis of Central Nervous Disorders

References

• Saha G. B. Fundamentals of Nuclear Pharmacy. Springer-Verlag, New York 1984
   Google Scholar
• Proceedings of New Frontiers in Diagnostic Imaging. Biomed. Bus. Int. December, 1987
   Google Scholar
• Croft B. Y. Single-Photon Emission Computed Tomography. Year Book Medical Publishers, Chicago 1986
   Google Scholar
• Positron Emission Tomography and Autoradiography—Principles and Applications for the Brain and Heart, M. E. Phelps, J. C. Mazziotta, H. R. Schelbert. Raven Press, New York 1986
   Google Scholar
• Kilbourn M. R. Fluorine-18 labeling of radiopharmaceuticals. Nuclear Science Series (NAS-NS-3203 Nuclear Medicine). National Academy Press, Washington, D. C. 1990
   Google Scholar
• Fowler J. S., Wolf A. P., Volkow N. D. New directions in positron emission tomography—part II. Ann. Rep. Med. Chem. 1990; 25: 261
   Google Scholar
• Fowler J. S., Wolf A. P. New directions in positron emission tomography. Ann. Rep. Med. Chem. 1989; 24: 277
   Google Scholar
• Kety S. S., Schmidt C. S. Nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure, and normal values. J. Clin. Invest. 1984; 27: 475
   Google Scholar
• Kety S. S. Regional cerebral blood flow: estimation by means of nonmetabolized tracers—an overview. Semin. Nucl. Med. 1985; 15: 324
   PubMed Web of Science ®Google Scholar
• Landau W. M., Freygang W. H., Rowland L. P., Sokoloff L., Kety S. S. The local circulation of the living brain: values in the unanesthetized and anesthetized cat. Trans. Am. Neurol. Assoc 1955; 80: 125
   Google Scholar
• Hoedt-Rasmussen L., Sveinsdottir E., Lassen N. A. Regional cerebral blood flow in man determined by intra-arterial injection of radioactive gas. Cir. Res. 1966; 18: 237
   PubMed Web of Science ®Google Scholar
• Veall N., Mallett B. I. The two-compartment model using Xe-133 inhalation and external counting. Acta Neurol. Scand. 1965; 14: 83, (Suppl.)
   Google Scholar
• Obrist W. D., Thompson H. K., Wang K. S., Wilkinson W. E. Regional cerebral blood flow estimated by 133Xenon inhalation. Stroke 1975; 6: 245
   PubMed Web of Science ®Google Scholar
• Volkow N. D., Mullani N., Gould L. K., Adler S. S., Gatley S. J. Sensitivity of measurements of regional brain activation with oxygen-15-water and PET to time of stimulation and period of image reconstruction. J. Nucl. Med. 1991; 32: 58
   PubMedGoogle Scholar
• Raichle M. E., Martin W. R. W., Herscovitch P., Mintun M. A., Markham J. Brain blood flow measured with intravenous H215O. II. Implementation and validation. J. Nucl. Med. 1983; 24: 790
   PubMed Web of Science ®Google Scholar
• Herscovitch P., Raichle M. E., Kilbourn M. R., et al. Measurement of cerebral blood flow and water permeability with positron emission tomography using O-15-water and C-11-butanol. J. Cereb. Blood Flow Metab. 1984; 5: 557, (Suppl.)
   Google Scholar
• Kung H. F. Brain radiopharmaceuticals. Radiopharmaceuticals: Progress and Clinical Perspectives, A. R. Fritzberg. CRC Press, Boca Raton, FL 1986; Vol. 1
   Google Scholar
• Blau M. Radiotracers for functional brain imaging. Semin. Nucl. Med. 1985; 25: 329
   Google Scholar
• Winchell H. S., Baldwin R. M., Lin T. H. Development of I-123 labeled amines for brain studies: localization of I-123 iodophenylalkylamines in rat brain. J. Nucl. Med. 1980; 21: 940
   PubMedGoogle Scholar
• Winchell H. S., Horst W. D., Braun L., et al. N-isopropyl (iodine-123) p-iodoamphetamine: single pass brain uptake and washout: binding to brain synaptosomes and localization in dog and monkey brain. J. Nucl. Med. 1980; 21: 947
   PubMed Web of Science ®Google Scholar
• Baldwin R. M., Lin T. H., Wu J. H. Synthesis and brain uptake of isomeric [123I]-iodoamphetamine derivatives. J. Lab. Comp. Radiopharm. 1982; 19: 1305
   Google Scholar
• Kizuka H., Elmaleh D. R., Brownell G. L. Synthesis and evaluation of p-iodophentermine (IP) as a brain perfusion imaging agent. Nucl. Med. Commun. 1986; 6: 49
   Google Scholar
• Hanson R. N., Jones G. S., Franke L., Kizuka H., Elmalek D. R. Preparation and evaluation of 3-[125I]iodo-4-aminoamphetamine as a brain perfusion imaging agent. Comparison with labeled phentermine derivatives. Int. J. Nucl. Biol. 1985; 12: 321
   PubMedGoogle Scholar
• Hanson R. N., Franke L. A., Webb N. Radioiodinated 1-(diethylaminopropyl)-4-phenylpiperazine: a potential brain imaging agent. Int. J. Nucl. Med. Biol. 1985; 12: 397
   PubMedGoogle Scholar
• Kung H. F., Blau M. Regional intracellular pH shift: a proposed new mechanism for radiopharmaceutical uptake in brain and other tissues. J. Nucl. Med. 1980; 21: 147
   PubMed Web of Science ®Google Scholar
• Kung H. F., Blau M. Synthesis of selenium-75 labeled tertiary diamines: new brain imaging agents. J. Med. Chem. 1980; 23: 1127
   PubMed Web of Science ®Google Scholar
• Tramposch K. M., Kung H. F., Blau M. Radioiodine labeled N,N,N' -tri-methyl-N' -(2-hydroxyl-3-alkyl-5-iodobenzyl)-1,3-propanediamines for brain perfusion imaging. J. Med. Chem. 1983; 26: 121
   PubMed Web of Science ®Google Scholar
• Kung H. F., Tramposch K. M., Blau M. A new brain perfusion imaging agent: [I-123]HIPDM: N,N,N' -trimethyl-N' -[2-hydroxyl-3-methyl-5-benzyl]-1,3-propanediamine. J. Nucl. Med. 1983; 24: 66
   PubMedGoogle Scholar
• Lucignani L., Nehlig A., Blasberg R. et al., Metabolism and kinetic considerations in the use of [125I]HIPDM for quantitative measurement of regional cerebral blood flow. J. Cereb. Blood Flow Metab. 1985; 5: 86
   PubMedGoogle Scholar
• Kuhl D. E., Barrio J. R., Huang S.-C., et al. Quantifying local cerebral blood flow by N-isopropyl-p-123I iodoamphetamine (IMP) tomography. J. Nucl. Med. 1982; 23: 196
   PubMedGoogle Scholar
• Fazio F., Lenzi G. L., Gerundini P., et al. Tomographic assessment of regional cerebral perfusion using intravenous I-123 HIPDM and a rotating gamma camera. J. Computer Asst. Tomogr. 1984; 8: 911
   PubMedGoogle Scholar
• Hill T. C., Holman L., Lovett R., et al. Initial experience with SPECT (single-photon computerized tomography) of the brain using N-isopropyl-I-123-p-iodoamphetamine: concise communication. J. Nucl. Med. 1982; 23: 191
   PubMedGoogle Scholar
• Holman B. L., Lee R. L., Hill T. C., Lovett R. D., Lister-James J. A comparison of two cerebral perfusion tracers, N-isopropyl-I-123-p-iodoamphetamine and I-123 HIPDM, in human. J. Nucl. Med. 1984; 25: 25
   PubMedGoogle Scholar
• Kung H. F., Blau M. A comparison of two cerebral perfusion tracers, N-isopropyl I-123-p-iodoamphetamine and I-123 HIPDM in the human, (letter). J. Nucl. Med. 1984; 25: 945
   PubMedGoogle Scholar
• Drayer B. P., Jaszczak R. J., Kung H. F., et al. In vivo quantitation of regional cerebral blood flow: the SPECT-HIPD method. Functional Radionuclide Imaging of the Brain, P. L. Magistretti. Raven Press, New York 1983; 193
   Google Scholar
• Karatzas N. D., Sfakianakis G. N., Papas D., Duncan R., Heal A., Serafini A., Kung H. F. Experimental increase in brain HIPDM uptake by hypercapnia. J. Nucl. Med. 1988; 29: 1675
   PubMedGoogle Scholar
• Som P., Oster Z. H., Yamamoto K., et al. Some factors affecting the cerebral and extracerebral accumulation of N-isopropyl-p-iodo-amphetamine (IAMP). Int. J. Nucl. Med. Biol. 1985; 12: 185
   PubMedGoogle Scholar
• Moretti J. L., Holman B. L., Delmon L., et al. Effect of antidepressant and narcoleptic drugs on N-isopropyl p-iodoamphetamine biodistribution in animals. J. Nucl. Med. 1987; 28: 354
   PubMedGoogle Scholar
• Burt R., Redolx V., Mock B. D. Acetazolamide on enhancement of HIPDM brain flow distribution imaging. J. Nucl. Med. 1986; 27: 1627
   PubMedGoogle Scholar
• Touya J. J., Rahimian J., Grubbs D. E., Corbus H. F., Bennett L. R. A noninvasive product for in vivo assay of a lung amine endothelial receptor. J. Nucl. Med. 1985; 26: 1302
   PubMedGoogle Scholar
• Slosman D. O., Brill A. B., Polla B. S., Alderson P. O. Evaluation of [iodine-125] N,N,N'-trimethyl-N' -[2-hydroxy-3-methyl-5-iodobenzyl]-1,3-propanediamine lung uptake using an isolated-perfused lung model. J. Nucl. Med. 1987; 28: 203
   PubMedGoogle Scholar
• Lassen N. A., Henriksen L., Holm S., et al. Cerebral blood flow tomography: Xenon-133 compared with isopropyl-amphetamine-iodine-123: concise communication. J. Nucl. Med. 1983; 24: P17
   PubMed Web of Science ®Google Scholar
• Hill T. C., Magistretti P. L., Holman B. L., et al. Assessment of regional cerebral blood flow (rCBF) in stroke using SPECT and N-isopropyl-(I-123)-p-iodoamphetamine (IMP). Stroke 1984; 15: 40
   PubMed Web of Science ®Google Scholar
• Steinling M., Destee A. Mismatch between iodine-123 and xenon-133 SPECT rCBF measurement. Clin. Nucl. Med. 1986; 11: 13
   PubMedGoogle Scholar
• Ackerman R. H. Of cerebral blood flow, stroke and SPECT. Stroke 1984; 15: 1
   PubMed Web of Science ®Google Scholar
• Holman B. L. Radionuclide Imaging of the Brain. Churchill Livingstone, New York 1985
   Google Scholar
• Johnson K. A., Holman B. L., Mueller S. P. Single photon computed emission tomography in Alzheimer's disease: abnormal iofetamine I-123 uptake reflect dementia severity. Arch. Neurol. 1988; 45: 392
   PubMedGoogle Scholar
• Shinichi N., Kinoshita K., Jinnouchi S., Hoshi H., Watanabe K. Comparative study of regional cerebral blood flow images by SPECT using Xenon-133, Iodine-123 IMP, and technetium-99m HM-PAO. J. Nucl. Med. 1989; 30: 157
   PubMedGoogle Scholar
• Holman B. L., Gibson R. E., Hill T. C., Eckelman W. C., Albright M., Reba R. C. Muscarinic acetylcholine receptors in Alzheimer's disease: in vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography. JAMA 1985; 254: 3063
   PubMedGoogle Scholar
• Magistretti P. L., Uren R., Blume H., et al. Delineation of epileptic focus by single photon emission tomography. Eur. J. Nucl. Med. 1982; 7: 484
   PubMedGoogle Scholar
• Lee B. I., Markand O. N., Siddiqui A. R., et al. Single photon emission computed tomography (SPECT) brain imaging using N,N,N' -trimethyl-N'-(2-hydroxy-3-methyl-5-123I-iodobenzyl) -1,3-propanediamine. 2HCl (HIPDM): intractable complex partial seizures. Neurology 1986; 36: 1471
   PubMedGoogle Scholar
• Leonard J. P., Nowotnik D. P., Neirinckx R. D. Tc-99m-d,1-HMPAO: a new radiopharmaceutical for imaging regional brain perfusion using SPECT—a comparison with iodine-123 HIPDM. J. Nucl. Med. 1986; 27: 1819
   PubMed Web of Science ®Google Scholar
• Neirinckx R. D., Canning L. R., Piper L. M. Technetium-99m-d,1-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J. Nucl. Med. 1987; 28: 191
   PubMed Web of Science ®Google Scholar
• Podreka I., Suess E., Goldenberg G., et al. Initial experience with technetium-99m HM-PAO brain SPECT. J. Nucl. Med. 1987; 28: 1657
   PubMed Web of Science ®Google Scholar
• Ballinger J. R., Reid R. H., Gulenchyn K. Y. Technetium-99m HM-PAO stereoisomers: differences in interaction with glutathione. J. Nucl. Med. 1998; 29: 1988
   Google Scholar
• Hung J. C., Corlija M., Volkert W. A., Holmes R. A. Kinetic analysis of technetium-99m d,1-HM-PAO decomposition in aqueous media. J. Nucl. Med. 1988; 29: 1568
   PubMedGoogle Scholar
• Troutner D. E., Volkert W. A., Hoffman T. J., et al. A neutral lipophilic complex of 99mTc with a multidentate amine oxime. Int. J. Appl. Radiat. Isot. 1984; 35: 467
   PubMedGoogle Scholar
• Sharp P. F., Smith F. W., Gemmell H. G., et al. Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J. Nucl. Med. 1986; 27: 171
   PubMedGoogle Scholar
• Cheesman E. H., Blanchette M. A., Calabrese J. C., et al. Technetium-99m complexes of ester derivatized diamine-dithiol ligands for imaging brain perfusion. Seventh Int Symp on Radiopharm Chem. GroningenThe Netherlands 1988; 421
   Google Scholar
• Walovitch R. C., Hill T. C., Garrity S. T., Cheesman E. H., Burgess B. A., et al. Characterization of technetium-99m-L,L-ECD for brain perfusion imaging. I. Pharmacology of technetium-99m ECD in nonhuman primates. J. Nucl. Med. 1989; 30: 1892
   PubMed Web of Science ®Google Scholar
• Walovitch R. C., Tam S. W., Cheesman E. H., Watson A. D., Garrity S. T., Williams S. J. Site selective localization of Tc-99m diamine dithiol complexes in rat brain hippocampus. J. Nucl. Med. 1987; 28: 731
   Google Scholar
• Kung H. F., Molnar M., Billings J., Wicks R., Blau M. Synthesis and biodistribution of neutral lipid-soluble Tc-99m complexes which cross the blood brain barrier. J. Nucl. Med. 1984; 25: 326
   PubMed Web of Science ®Google Scholar
• Efange S. M. N., Kung H. F., Billings J., Blau M. The synthesis and biodistribution of [99mTc]piperidinyl bis(aminoethanethiol) complexes: potential brain perfusion imaging agents for SPECT. J. Med. Chem. 1988; 31: 1043
   PubMedGoogle Scholar
• Efange S. M. N., Kung H. F., Billings J., Guo Y.-Z., Blau M. Tc-99m bis(amino-ethanethiol) (BAT) complexes with amine side chains—potential brain perfusion imaging agents for SPECT. J. Nucl. Med. 1987; 28: 1012
   PubMed Web of Science ®Google Scholar
• Kung H. F., Guo Y.-Z., Yu C.-C., Billings J., Subramanyam V., Calabrese J. New brain perfusion imaging agents based on Tc-99m bis-amino-ethanethiol (BAT) complexes: stereoisomers and biodistribution. J. Med. Chem. 1989; 32: 433
   PubMed Web of Science ®Google Scholar
• Scheffel U., Goldfarb H. W., Lever S. Z., Gungon R. L., Burns H. D., Wagner H. N., Jr. Comparison of technetium-99m aminoalkyl diaminodithiol analogs as potential brain blood flow imaging agents. J. Nucl. Med. 1988; 29: 73
   PubMed Web of Science ®Google Scholar
• Watson A. D., Walovitch R. C., Belonga B. Q., Cheesman E. H. The chemistry and pharmacology of triaminedithiol technetium-based brain perfusion agents. J. Labelled Comp. Radiopharm. 1987; 23: 1150
   Google Scholar
• Narra R. K., Nunn A. D., Kuczynski B. L., DiRocco R. J., Feld T., Silva D. A., Eckelman W. C. A neutral lipophilic technetium-99m complex for regional cerebral blood flow imaging. J. Nucl. Med. 1990; 31: 1370
   PubMedGoogle Scholar
• Kuczynski B. L., Silva D., Feld T. et al., Autoradiography of monkey brain with SQ 32097: a new Tc-99m-labeled brain imaging agent. J. Nucl. Med. 1987; 28: 1081
   Google Scholar
• Coleman R. E., Maturi M., Nunn A. D., Eckelman W. C., Juri P. N., Cobb F. R. Imaging of myocardial perfusion with Tc-99m SQ 30217: dog and human studies. J. Nucl. Med. 1986; 27: 893
   Google Scholar
• Treher E. N., Francesconi L. C., Gougoutas J., Malley M. F., Nunn A. D. The first monocapped tris dioxime complexes of a transition metal: synthesis and structural characterization of [Tc-X(DIOXIMEH)2(DIOXIME)(B-R)]. Inorg. Chem. 1989; 28: 3411
   Web of Science ®Google Scholar
• Sokoloff L. chap. 1. Positron Emission Tomography and Autoradiography—Principles and Applications for the Brain and Heart, M. E. Phelps, J. C. Mazziotta, H. R. Schelbert. Raven Press, New York 1986
   Google Scholar
• Ido T., Wan C. N., Fowler J. S., Wolf A. P. Fluorination with F2. A convenient synthesis of 2-deoxy-2-fluoro-D-glucose. J. Org. Chem. 1977; 42: 2341
   Web of Science ®Google Scholar
• Ido T., Wan C. N., Casella V., Fowler J. S., Wolf A. P., Reivich M., Kuhl D. E. Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose, and C-14–2-deoxy-2-fluoro-D-glucose. J. Lab. Comp. Radipharm. 1978; 14: 175
   Web of Science ®Google Scholar
• Sokoloff L., Reivich M., Kennedy C., Des Rosiers M., Patlak C., Pettigrew C., Sakurada O., Shinohara M. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthesized albino rats. J. Neurochem. 1977; 28: 897
   PubMed Web of Science ®Google Scholar
• Reivich M., Kuhl D., Wolf A., Greenberg J., Phelps M., Ido T., Cassella V., Fowler J., Hoffman E., Alavi A., Som P., Sokoloff L. The [18F]fluorodeoxyglucose method for the measurement of local glucose metabolism in man. Circ. Res. 1979; 44: 127
   PubMed Web of Science ®Google Scholar
• Phelps M. E., Maziotta J. C. Positron emission tomography: human brain function and biochemistry. Science 1985; 228: 799
   PubMed Web of Science ®Google Scholar
• Jolles P. R., Chapman P. R., Alavi A. PET, CT, and MRI in the evaluation of neuropsychiatric disorders: current application. J. Nucl. Med. 1989; 30: 1589
   PubMedGoogle Scholar
• Minn H., Paul R., Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine fluorodeoxyglucose. Nucl. Med. 1988; 29: 1521
   Google Scholar
• Brooks R. A., Di Chiro G., Zukerberg B. W., Bairamian D., Larson S. M. Test retest studies of cerebral glucose metabolism using fluorine-18 deoxyglucose: validation of method. J. Nucl. Med. 1987; 28: 53
   PubMedGoogle Scholar
• Di Chiro G., Brooks R. A. Quantitation: blessing and curse. J. Nucl. Med. 1988; 29: 1603
   PubMedGoogle Scholar
• Magata Y., Saji H., Arano Y., Horiuchi K., Torizuka K., Yokoyama A. Procurement of radioiodinated glucose derivatives and its biological character. Nucl. Med. Biol. 1987; 14: 7
   Google Scholar
• Goodman M. M., Callahan A. P., Knapp F. F., Jr. Design, synthesis and evaluation of 2-deoxy-2-vinyl-branched carbohydrates as potential brain imaging agents. Sixth Int. Symp. on Radiopharm. Chem., Boston 1986; 243
   Google Scholar
• Saji H., Magata Y., Ohmomo Y., Arano Y., Horiuchi K., Yokoyama A. Radioiodinated glucose derivative with interaction with hexokinase. J. Nucl. Med. 1988; 29: 787, (Abstr.)
   Google Scholar
• Goodman M. M., Kabalka G. W., Meng X., Danial G. B., Longford C. P. Synthesis and evaluation of radioiodinated 4-O-(E)-3-iodopropen-2-yl-D-glucose and derivatives as potential heart imaging agent. J. Nucl. Med. 1990; 31: 900, (Abstr.)
   Google Scholar
• Dopamine Receptors, I. Creese, C. M. Fraser. Alan R. Liss, New York 1987
   Google Scholar
• Seeman P. Brain dopamine receptors. Pharmacol. Rev. 1980; 32: 229
   PubMed Web of Science ®Google Scholar
• Beaulieu M. Clinical importance of D-1 and D-2 receptors. Can. J. Neurol. Sci. 1987; 14: 402
   PubMedGoogle Scholar
• Waddington J. L. Behavioural correlates of the action of selective D-1 dopamine receptor antagonists. Impact of SCH 23390 and SKF 83566, and functionally interactive D-1:D-2 receptor systems. Biochem. Pharmacol. 1986; 35: 3661
   PubMedGoogle Scholar
• Stoof J. C., Kebabian J. W. Two dopamine receptors: biochemistry, physiology, and pharmacology. Life Sci. 1984; 35: 228
   Google Scholar
• Waddington J. L., O'Boyle K. M. The D-1 dopamine receptor and the search for its functional role: from neurochemistry to behaviour. Rev. Neurosci. 1987; 1: 157
   PubMedGoogle Scholar
• Waddington J. L. Sight and insight: brain dopamine receptor occupancy by neuroleptics visualised in living schizophrenic patients by PET. Br. J. Psychiat. 1989; 154: 433
   PubMedGoogle Scholar
• Waddington J. L., O'Boyle K. M. Drugs acting on brain dopamine receptors: a conceptual reevaluation five years after the first selective D-1 antagonist. Pharmacol. Ther. 1989; 43: 1
   PubMedGoogle Scholar
• Waddington J. L., O'Boyle K. M. The D-1 dopamine receptor and the search for its functional role: from neurochemistry to behaviour. Rev. Neurosc. 1987; 1: 157
   PubMedGoogle Scholar
• Kebabian J. W., Calne D. B. Multiple receptors for dopamine. Nature 1979; 277: 93
   PubMed Web of Science ®Google Scholar
• Saller C. F., Salama A. I. Dopamine receptor subtypes: in vivo biochemical evidence for functional interaction. Eur. J. Pharmacol. 1985; 109: 297
   PubMedGoogle Scholar
• Walters J. R., Bergstrom D. A., Carlson J. H., et al. D1 dopamine receptor activation required for post-synaptic expression of D2 agonist effects. Science 1987; 236: 719
   PubMed Web of Science ®Google Scholar
• Robertson G. S., Robertson H. A. D1 and D2 dopamine agonist synergism: separate sites of action. TIPS 1987; 8: 295
   Google Scholar
• Neurobiology of Central D-1 Dopamine Receptors, G. R. Breese, I. Creese. Plenum Press, New York 1986
   Google Scholar
• Wong D. F., Wagner H. N., Dannals R. J., et al. Effects of age on dopamine and serotonin receptors measured by positron tomograph in the human brain. Science 1984; 226: 1393
   PubMed Web of Science ®Google Scholar
• Rinne J. O., Lönnberg P., Marjamäki P. Age-dependent decline in human brain dopamine D1 and D2 receptors. Brain Res. 1990; 508: 349
   PubMedGoogle Scholar
• Rinne U. K., Laihinen A., Rinne J. O., Någren K., Bergman J., Ruotsalainen U. PET demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov. Disord. 1990; 5: 55
   PubMedGoogle Scholar
• Rinne J. O., Rinne U. K., Laakso K. Dopamine D-1 receptors in the Parkinsonian brain. Brain Res. 1985; 359: 306
   PubMedGoogle Scholar
• Raisman R., Cash R., Ruberg M., et al. Binding of [3H]SCH 23390 to D-1 receptors in the putamen of control and Parkinsonian subjects. Eur. J. Pharmacol. 1985; 113: 467
   PubMedGoogle Scholar
• Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179
   PubMed Web of Science ®Google Scholar
• Creese I., Fraser C. M. Dopamine Receptors. Alan R. Liss, New York 1987
   Google Scholar
• Seeman P., et al. Link between D1 and D2 dopamine receptors in reduced in schizophrenia and Huntington diseased brain. Proc. Natl. Acad. Sci. USA 1989; 86: 156
   Google Scholar
• Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1: 133
   PubMed Web of Science ®Google Scholar
• Wagner H. N., Burns H. D., Dannals R. J. et al., Imaging dopamine receptors in the human brain by positron tomography. Science 1983; 221: 1264
   PubMed Web of Science ®Google Scholar
• Wong D. F., Minkin E., Wilson A. A., Young L. T., Dannals R. F., Ravert H. T., Wagner H. N., Jr. In vivo studies of D2 dopamine receptors with C-11 and 1–125 iodobenzamide. J. Nucl. Med. 1990; 31: 882
   Google Scholar
• Wong D. F., Young D., Young L. T., Chan B., Minkin E., Burkhardt D., Wilson P. D., Dannals R. F., Wilson A. A., Ravert H. T., Natarajan T. K., Shaya E., Pearlson G., Tune L., Singer H., Gjedde A., Wagner H. N., Jr. Further validation studies of C-11 NMSP measurements of PET dopamine and serotonin receptors in neuropsychiatric illness. J. Nucl. Med. 1990; 31: 809
   Google Scholar
• Wong D. F., Wagner H. N., Jr., Tune L. E., et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 243: 1558
   Google Scholar
• Wong D. F., Wagner H. N., Jr., Pearlson G., Dannals R. F., Links J. M., Ravert H. T., Wilson A. A., Suneja S., Bjorvvinsen E., Kuhar M. J., Tune L. Dopamine receptor binding of C-11–3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: a preliminary report. Psychopharmacol. Bull. 1985; 21: 595
   PubMed Web of Science ®Google Scholar
• Farde L., Wiesel F.-A., Stone-Elander S., Halldin C., Nordström A.-L., Hall H., Sedvall G. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch. Gen. Psychiat. 1990; 47: 213
   PubMed Web of Science ®Google Scholar
• Farde L., Halldin C., Stone-Elander S., et al. PET analysis of human dopamine receptor subtypes using 11C-SCH-23390 and 11C-raclopride. Psychopharmacology 1987; 92: 278
   PubMed Web of Science ®Google Scholar
• Farde L., Wiesel F.-A., Hall C., Halldin C., Stone-Elander S., Sedvall G. No D2 receptor increase in PET study of schizophrenia. Arch. Gen. Psychiat. 1987; 44: 671
   PubMed Web of Science ®Google Scholar
• Farde L., Hall H., Ehrin E., et al. Quantitative analysis of D-2 dopamine receptor binding in the living human brain by PET. Science 1986; 231: 258
   PubMed Web of Science ®Google Scholar
• Farde L., Ehrin E., Eriksson L. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc. Natl. Acad. Sci. USA 1985; 82: 3863
   PubMed Web of Science ®Google Scholar
• Swart J. A. A., Korf J. Quantification of dopamine D2 receptors by irreversible tracer binding in the living human brain: the model-dependent correction of metabolites (letter). J. Cereb. Blood Flow Metab. 1989; 9: 906
   PubMedGoogle Scholar
• Florvall L., Ögren S. O. Potential neuroleptic agents. 2,6-dialkoxybenzamide derivatives with potent receptor blocking activities. J. Med. Chem. 1982; 25: 1280
   PubMed Web of Science ®Google Scholar
• Ögren S. O., Hall H., Kohler C. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur. J. Pharmacol. 1984; 102: 459
   PubMed Web of Science ®Google Scholar
• de Paulis T., Kumar Y., Johansson L., Tamsby S., Florvall L., Hall H., Angeby-Moller K., Ogren S.-O. Potential neuroleptic agents. III. Chemistry and antidopaminergic properties of substituted 6-methoxysalicylamides. J. Med. Chem. 1985; 28: 1263
   PubMed Web of Science ®Google Scholar
• Hall H., Wedel I. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D-2 receptors in the rat striatum. Acta Pharmacol. Toxicol. 1986; 58: 368
   PubMedGoogle Scholar
• Kung H. F., Billings J. J., Guo Y.-Z., Blau M., Ackerhalt R. A. Preparation and biodistribution of [125I]IBZP: A potential CNS D-1 dopamine receptor imaging agent. Nucl. Med. Biol. 1988; 15: 187
   Google Scholar
• Kung H. F., Billings J. J., Guo Y.-Z., Xu X., Mach R. H., Blau M., Ackerhalt R. A. Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. Nucl. Med. Biol. 1988; 15: 195
   Web of Science ®Google Scholar
• Chi D. Y., Kilbourn M. R., Katzenellenbogen J. A., Brodack J. W., Welch M. J. Syntheses of no-carrier added N-([18F]fluoroalkyl)spiperone derivatives. Appl. Radiat, Isot. 1986; 37: 1173
   Web of Science ®Google Scholar
• Kiesewetter D. O., Eckelman W. C., Cohen R. W., et al. Syntheses and D2 receptor affinities of derivatives of spiperone containing aliphatic halogens. Appl. Radiat. Isot. 1986; 12: 1181
   Google Scholar
• Welch M. J., Chi D. Y., Mathias C. J., et al. Biodistribution of N-alkyl and N-fluoralkyl derivatives of spiroperidol; radiopharmaceuticals for PET studies of dopamine receptors. Int. J. Nucl. Med. Biol. 1986; 12: 523
   Google Scholar
• Lannoye G. S., Moerlein S. M., Parkinson D., Welch M. J. N-fluoroalkylated and N-alkylated analogues of the dopaminergic D-2 receptor antagonist raclopride. J. Med. Chem. 1990; 33: 2430
   PubMedGoogle Scholar
• Satyamurthy N., Bida G. T., Barrio J. R., et al. No-carrier-added 3-(2'-[18F]-fluoroethyl) spiperone, a new dopamine receptor-binding tracer for positron emission tomography. Int. Nucl. Med. Biol. 1986; 13: 617
   Google Scholar
• Satyamurthy N., Bida G. T., Luxen A., Barrio J. R. Syntheses of 3-(2'-[18F]fluoroethyl)-spiperone, a dopamine receptor-binding radiopharmaceutical for PET. J. Lab. Comp. Radiopharm. 1986; 23: 1045
   Google Scholar
• Coenen H. H., Laufer P., Stoecklin G., et al. 3-N-(2-[18F]-fluoroethyl)-spiperone: a novel ligand for cerebral dopamine receptor studies with PET. Life Sci. 1987; 40: 81
   PubMedGoogle Scholar
• Nakatzuka I., Saji H., Shiba K., et al. In vitro evaluation of radioiodinated butyrophenone as a radiotracer for dopamine receptor study. Life Sci. 1989; 41: 1987
   Google Scholar
• Saji H., Nakatzuka I., Shiba K., et al. Radioiodinated 2-iodospiperone: a new radioligand for in vivo dopamine receptor study. Life Sci. 1987; 41: 1999
   PubMedGoogle Scholar
• Shiue C. Y., Bai L-Q., Teng R. R., Wolf A. P. Syntheses of no-carrier-added (NCA) [18F]fluoroalkyl halides and their application in the synthesis of [18F]fluoroalkyl derivatives of neurotransmitter receptor active compounds. J. Lab. Comp. Radiopharm. 1987; 24: 55
   Google Scholar
• Arnett C. D., Fowler J. S., Wolf A. P. [18F]-N-methyl-spiroperidol: the radioligand of choice for PET studies of the dopamine receptor in human brain. Life Sci. 1985; 36: 1359
   PubMedGoogle Scholar
• Owen F., Crawley J., Cross M., et al. Dopamine D2 receptors and schizophrenia. Br. Psychopharm. Monogr. 1985; 216: 227
   Google Scholar
• Crawley J. C. W., Crow T. J., Johnstone E. C., et al. Uptake of 77Br-spiperone in the striata of schizophrenic patients and controls. Nucl. Med. Comm. 1986; 7: 599
   PubMedGoogle Scholar
• Garnett E. S., Firnau G., Nahmias C. Dopamine visualised in the basal ganglia of living man. Nature 1983; 305: 137
   PubMedGoogle Scholar
• Martin W. R. W., Boyes B. E., Leenders K. L., Patlak C. S. A method for quantitative analysis of 6-fluorodopa uptake data from positron emission tomography. J. Cereb. Blood Flow Metab. 1985; 5: S593, (Suppl. 1)
   Google Scholar
• Martin W. R. W., Palmer M. R., Patlak C. S., Calne D. B. Nigrostriatal function in humans studied with positron emission tomography. Ann. Neurol. 1989; 26: 535
   PubMedGoogle Scholar
• Firnau G., Garnett E. S., Chan P. K. H., Belbeck L. W. Intracerebral dopamine metabolism studied by a novel radioisotope technique. J. Pharm. Pharmacol. 1976; 28: 584
   PubMedGoogle Scholar
• Garnet E. S., Firnau G., Chan P. K. H., Sood S., Belbeck L. W. [18F]-Fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine. Proc. Natl. Acad. Sci. USA 1978; 75: 464
   PubMedGoogle Scholar
• Firnau G., Sood S., Chirakal R., Nahmias C., Garnett E. S. Cerebral metabolism of 6-[18F]Fluoro-L-dopa for the in vivo study of intracerebral dopamine. J. Neurochem. 1987; 48: 1077
   PubMedGoogle Scholar
• Cumming P., Boyes B. E., Martin W. R. W., et al. The metabolism of [18F]6-fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat. J. Neurochem. 1987; 48: 601
   PubMedGoogle Scholar
• Leenders K. L. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol. 1990; 47: 1290
   PubMed Web of Science ®Google Scholar
• Brooks D. J., Ibanez V., Sawle G. V., Quinn N., Lees A. J., Mathias C. J., Bannister R., Marsden C. D., Frackowiak R. S. J. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol. 1990; 28: 547
   PubMed Web of Science ®Google Scholar
• Miletich R. S., Bankiewicz K. S., Plunkett R. J. Fetal brain graph and Parkinson's disease. Science 1990; 250: 1434
   PubMedGoogle Scholar
• Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Franckowiak R., Leenders K. L., Rothwell J. C., Madrdsen C. D., Bjorklund A. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990; 247: 574
   PubMed Web of Science ®Google Scholar